Similarly, for high HIF1-α expression in T2DM patients at risk of developing BC, HIF1 targeting may prove a promising therapeutic strategy, whereas for BC patients at risk of developing T2DM, HIF1 targeting may potentially alleviate disease prognostic outcome. The gene discussed is HIF1A; the disease is breast cancer.